EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medpace Holdings's Enterprise Value is $11,494 Mil.
Medpace Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $336 Mil. Therefore, Medpace Holdings's EV-to-EBIT for today is 34.20.
The historical rank and industry rank for Medpace Holdings's EV-to-EBIT or its related term are showing as below:
MEDP'
s EV-to-EBIT Range Over the Past 10 Years
Min: 18.31 Med: 27.66 Max: 51.72
Current: 34.25
During the past 11 years, the highest EV-to-EBIT of Medpace Holdings was 51.72. The lowest was 18.31. And the median was 27.66.
MEDP's EV-to-EBIT is ranked worse than 75.23% of 109
companies
in the Medical Diagnostics & Research industry
Industry Median: 18.95
vs MEDP: 34.25
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Medpace Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $9,323 Mil.
Medpace Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $336 Mil. Medpace Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.61%.
Medpace Holdings EV-to-EBIT Historical Data
The historical data trend for Medpace Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Medpace Holdings Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBIT
23.14
28.63
37.79
24.27
27.68
Medpace Holdings Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBIT
24.27
19.92
23.86
23.81
27.68
Competitive Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings EV-to-EBIT Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's EV-to-EBIT falls into.
Medpace Holdings EV-to-EBIT Calculation
Medpace Holdings's EV-to-EBIT for today is calculated as:
Medpace Holdings's current Enterprise Value is $11,494 Mil.
Medpace Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $336 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medpace Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $9,323 Mil.
Medpace Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $336 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Medpace Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Medpace Holdings (Medpace Holdings) Business Description
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEDP has been successfully added to your 